-
Tytuł:
-
Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort.
-
Autorzy:
-
Hu C; Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
Li S; Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
Xie Z; Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
You H; Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
Jiang H; Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
Shi Y; Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
Qi W; Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
Zhao J; Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
Wang Q; Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
Tian X; Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
Li M; Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
Zhao Y; Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
Zeng X; Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
-
Źródło:
-
Frontiers in immunology [Front Immunol] 2021 Jul 02; Vol. 12, pp. 648881. Date of Electronic Publication: 2021 Jul 02 (Print Publication: 2021).
-
Typ publikacji:
-
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: [Lausanne : Frontiers Research Foundation]
-
MeSH Terms:
-
Reagent Kits, Diagnostic*
Antibodies, Antiphospholipid/*immunology
Antiphospholipid Syndrome/*immunology
Pathology, Molecular/*methods
Adult ; Antibodies, Anticardiolipin/immunology ; Antiphospholipid Syndrome/diagnosis ; Cohort Studies ; Enzyme-Linked Immunosorbent Assay/methods ; Female ; Humans ; Immunoglobulin A/immunology ; Immunoglobulin G/immunology ; Immunoglobulin M/immunology ; Male ; Middle Aged ; Pathology, Molecular/instrumentation ; Reproducibility of Results ; Sensitivity and Specificity ; Young Adult ; beta 2-Glycoprotein I/immunology
-
References:
-
Autoimmun Rev. 2014 Jan;13(1):59-63. (PMID: 24075882)
Curr Rheumatol Rep. 2020 Jun 19;22(8):38. (PMID: 32562091)
J Thromb Haemost. 2010 Feb;8(2):237-42. (PMID: 19874470)
N Engl J Med. 2018 May 24;378(21):2010-2021. (PMID: 29791828)
Immunol Invest. 2020 Feb;49(1-2):58-68. (PMID: 31401900)
PLoS One. 2019 Jul 24;14(7):e0220033. (PMID: 31339913)
Arthritis Rheum. 2012 Jul;64(7):2311-8. (PMID: 22275304)
Int J Lab Hematol. 2011 Feb;33(1):97-108. (PMID: 20813022)
Int J Lab Hematol. 2012 Dec;34(6):630-40. (PMID: 22827598)
Int J Lab Hematol. 2014 Jun;36(3):352-63. (PMID: 24750682)
Int J Lab Hematol. 2020 Jun;42 Suppl 1:49-58. (PMID: 32543059)
J Immunol Res. 2019 Dec 1;2019:8380214. (PMID: 31886311)
Front Immunol. 2020 Oct 05;11:568503. (PMID: 33123140)
J Thromb Haemost. 2006 Feb;4(2):295-306. (PMID: 16420554)
Ann Rheum Dis. 2003 Dec;62(12):1127. (PMID: 14644846)
Thromb Res. 2011 Dec;128(6):565-9. (PMID: 21529896)
Med Sci Monit. 2018 Sep 26;24:6816-6822. (PMID: 30256771)
Immunopharmacol Immunotoxicol. 2016;38(1):14-20. (PMID: 26525648)
Autoimmun Rev. 2018 Oct;17(10):956-966. (PMID: 30118899)
Autoimmun Rev. 2018 Sep;17(9):866-872. (PMID: 30005859)
Clin Rheumatol. 2019 Feb;38(2):371-378. (PMID: 30099654)
Thromb Haemost. 2019 May;119(5):797-806. (PMID: 30822809)
Ann Rheum Dis. 2019 Oct;78(10):1296-1304. (PMID: 31092409)
J Clin Med Res. 2020 May;12(5):286-292. (PMID: 32489503)
J Immunol Methods. 2012 May 31;379(1-2):48-52. (PMID: 22421684)
Int J Lab Hematol. 2016 Apr;38(2):172-82. (PMID: 26847159)
Res Pract Thromb Haemost. 2019 May 26;3(3):515-527. (PMID: 31294336)
J Thromb Haemost. 2018 Apr;16(4):809-813. (PMID: 29532986)
Ann Rheum Dis. 2011 Aug;70(8):1517-8. (PMID: 21402561)
J Thromb Haemost. 2018 Oct;16(10):2016-2023. (PMID: 30079628)
-
Contributed Indexing:
-
Keywords: anti-cardiolipin; anti-β2 glycoprotein-I; antiphospholipid antibodies; antiphospholipid syndrome; chemiluminescent immunoassay; enzyme-linked immunosorbent assay
-
Substance Nomenclature:
-
0 (Antibodies, Anticardiolipin)
0 (Antibodies, Antiphospholipid)
0 (Immunoglobulin A)
0 (Immunoglobulin G)
0 (Immunoglobulin M)
0 (Reagent Kits, Diagnostic)
0 (beta 2-Glycoprotein I)
-
Entry Date(s):
-
Date Created: 20210719 Date Completed: 20210927 Latest Revision: 20210927
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC8283786
-
DOI:
-
10.3389/fimmu.2021.648881
-
PMID:
-
34276646
-
Background: Diagnosis of antiphospholipid syndrome (APS) is based on the positivity of laboratory criteria antiphospholipid antibodies (aPLs). Test results for aPLs could be contradictory among different detection methods as well as commercial manufacturers. This study aimed to assess and compare the diagnostic and analytic performances of four commercial assays prevalently used in China.
Methods: A total of 313 patients including 100 patients diagnosed with primary APS, 52 with APS secondary to SLE, 71 with SLE, and 90 health controls were recruited. Serum IgG, IgM, and IgA for aCL, and a β 2GPI antibodies were detected with two ELISA and two CLIA systems, and test system with the best diagnostic value was explored of its correlation with key clinical features.
Results: CLIA by YHLO Biotech Co. was considered as the system with the best predictive power, where 58.55 and 57.89% of APS patients were positive for aCL or a β 2GPI for at least one antibody (IgG or IgM or IgA). Overall, CLIA showed better performance characteristics than traditional ELISA test systems.
Conclusion: CLIA was considered as a better platform for aPL detection in APS diagnosis. A combination of other detection platforms could assist in differential diagnosis as well as in identifying high-risk patients.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Hu, Li, Xie, You, Jiang, Shi, Qi, Zhao, Wang, Tian, Li, Zhao and Zeng.)
